retatrutide vs cagrilintide and Retatrutide: Why Most Researchers Are Asking the Wrong Question Retatrutide + Cagrilintide: The Weight

Vu TD, Sohng W, Jang E, Choi D, Chung H

PRNewswire / Investor Release (2025) 3

Plaintiffs allege the drug labels failed to disclose the risk of NAION or other severe vision complications, depriving patients of the ability to make informed treatment decisions

Model performance of efficacy was further assessed by applying the model derived from our self-report data in a sample of 642 people who had provided HealthKit EHR data but had not completed the GLP1 survey, and hence were not used in the construction of the model

We are also hoping to better understand the personal experiences of people who have used compounded GLP-1 products